By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Seattle Genetics, Inc. 

21823 - 30th Drive S.E.

Bothell  Washington  98021  U.S.A.
Phone: 425-527-4000 Fax: 425-527-4001

Committed to improving patient outcomes
At Seattle Genetics, we are committed to developing innovative antibody-based therapies that improve clinical outcomes for patients with cancer and autoimmune diseases. We are dedicated to addressing unmet medical need, and strive to achieve that goal through an unwavering commitment to excellence in clinical development.

Focusing on Clinical Development
Seattle Genetics is a clinical stage biotechnology company advancing a broad product pipeline of antibody-based therapies. Our lead program, brentuximab vedotin (SGN-35), is in a pivotal trial under a Special Protocol Assessment with the FDA for patients with relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is empowered by Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. In addition, we are conducting clinical trials with four other product candidates, lintuzumab (SGN-33), dacetuzumab (SGN-40) and SGN-75, for the treatment of cancer, and SGN-70, for autoimmune diseases. We are also advancing a pipeline of promising preclinical candidates and have robust research and development capabilities that are our engine for innovation and long-term growth.

Our proprietary ADC technology empowers antibodies by stably linking them to cell-killing drug payloads. The drug payload is inactive until released from the antibody inside the targeted cancer cell, thereby sparing normal tissue the toxicity of traditional chemotherapy. In addition to brentuximab vedotin, SGN-75 is an ADC that is in a phase I clinical trial and we are developing several preclinical ADC product candidates, including ASG-5ME, which is advancing towards a planned 2010 clinical trial for solid tumors.

Expanding Our Opportunities Through Collaboration
Collaborating with leading biopharmaceutical companies is a cornerstone of Seattle Genetics' business strategy. Product-focused collaborations, such as our exclusive worldwide collaboration agreement with Genentech (a wholly owned member of the Roche Group) to develop and commercialize dacetuzumab, provide significant near- and mid-term funding while bringing in additional resources and expertise to support, advance and expand promising development programs. Collaboration and license agreements around our proprietary ADC technology also generate cash for the company - more than $75 million to date - while providing further clinical validation of the ADC platform and, in some cases, opening the door to new product development opportunities.

Key Statistics

Ownership: Public

Web Site: Seattle Genetics
Symbol: SGEN



Celera Corporation  Seeking to jointly discover and develop antibody-based therapies for cancer.

Applied Molecular Evolution/Eli Lilly 


Company News
Seattle Genetics (SGEN) Reports Fourth Quarter And Year 2015 Financial Results 2/10/2016 10:26:28 AM
Seattle Genetics (SGEN) Announces Commercial And Regulatory Progress Under ADCETRIS (Brentuximab Vedotin) Collaboration With Takeda (TKPYY) 2/4/2016 8:07:49 AM
Seattle Genetics (SGEN) To Host Conference Call And Webcast Discussion Of Fourth Quarter And Year 2015 Financial Results On February 9, 2016 1/20/2016 8:10:19 AM
Seattle Genetics (SGEN) To Present At The J.P. Morgan Healthcare Conference 1/5/2016 11:24:14 AM
Seattle Genetics (SGEN) And Bristol-Myers Squibb (BMY) Announce Initiation Of Phase 1/2 Clinical Trial Of ADCETRIS┬« (Brentuximab Vedotin) In Combination With Opdivo (Nivolumab) In Relapsed Or Refractory Non-Hodgkin Lymphoma 12/23/2015 10:29:45 AM
Seattle Genetics (SGEN) Highlights ADCETRIS (Brentuximab Vedotin) Data Presentations In Frontline Non-Hodgkin Lymphoma At American Society of Hematology 2015 12/8/2015 12:40:20 PM
Seattle Genetics (SGEN) Highlights Vadastuximab Talirine (SGN-CD33A) Data Presentations In Patients With Acute Myeloid Leukemia At American Society of Hematology 2015 12/7/2015 1:22:51 PM
Seattle Genetics (SGEN) Demonstrates Commitment To Improve Hodgkin Lymphoma (HL) Treatment Paradigm Through Multiple ADCETRIS┬« (Brentuximab Vedotin) Data Presentations At American Society of Hematology 2015 12/7/2015 10:14:48 AM
Seattle Genetics (SGEN) To Present At Oppenheimer Healthcare Conference 12/2/2015 10:48:52 AM
Seattle Genetics (SGEN) To Webcast Investor And Analyst Event At American Society of Hematology Annual Meeting 12/1/2015 10:27:24 AM